TP53 and neoplasm: Unfortunately, C-myc overexpression [79], KRAS mutations [80], HER-2 gene amplification [81], and TP53 mutations [82] do not seem to be correlated with tumor prognosis, and no alternative therapeutic options to the conventional chemotherapy regimen are available at the moment.